Studies on the impact of CXCR3 ligand in IL‐7/IL‐7Rα‐Fc–mediated antitumor activity revealed that when treating mice with lung cancer using IL‐7/IL‐7Rα‐Fc, it raised the levels of chemokine ligands CXCL9 and CXCL10, IFNγ, and IL‐12, but it reduced the levels of IL‐10 and TGF‐β [119]. The gene discussed is IL7; the disease is lung cancer.